SCS Capital Management’s Sana Biotechnology SANA Stock Holding History

SCS Capital Management’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$284K	Hold	81,250	–	–	﹤0.01%	428
2026 Q1	$234K	Hold	81,250	–	–	﹤0.01%	436
2025 Q4	$331K	Sell	81,250 -70	-0.1%	-$313	﹤0.01%	418
2025 Q3	$289K	Sell	81,320 -132	-0.2%	-$477	﹤0.01%	452
2025 Q2	$222K	Hold	81,452	–	–	﹤0.01%	511
2025 Q1	$137K	Buy	+81,452	New	+$228K	﹤0.01%	499

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

SCS Capital Management's SANA Position: Q2 2026 in Review

SCS Capital Management held its Sana Biotechnology (SANA) position steady in Q2 2026 at 81,250 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #428.

SCS Capital Management first reported a position in SANA in Q1 2025 and has held it in 6 quarters since. The position peaked at $331K in Q4 2025. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

SCS Capital Management held 81,250 shares of Sana Biotechnology worth $284K as of Q2 2026.
SCS Capital Management left its Sana Biotechnology share count unchanged in Q2 2026.
Sana Biotechnology made up ﹤0.01% of SCS Capital Management's portfolio in Q2 2026, its #428 holding.
SCS Capital Management first reported a position in Sana Biotechnology in Q1 2025 and has held it in 6 quarters since.
SCS Capital Management's Sana Biotechnology position peaked at $331K in Q4 2025.
211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.